Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F A Anderer

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
Klinische Wochenschrift|February 4, 1985
The clinical validity of circulating tumor-associated antigens CEA and CA 19-9 in primary diagnosis and follow-up of patients with gastrointestinal malignanciesH J Staab, T Brümmendorf, A Hornung, et al.
Biochemical and Biophysical Research Communications|November 14, 1984
Cell fusion responsible for horizontal oncogenesis by human tumors in nude miceJ Kömpf, H J Staab, H Heilbronner, et al.
British Journal of Cancer|May 1, 1982
Prognostic value of preoperative serum CEA level compared to clinical staging: II. Stomach cancerH J Staab, F A Anderer, T Brümmendorf, et al.
Oncodevelopmental Biology and Medicine : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 1980
Carcinoembryonic antigen (CEA) measurements as an aid to management of patients with lung cancer treated by radiotherapyL M Ahlemann, H J Staab, H L Koch, et al.
British Journal of Cancer|November 1, 1981
Prognostic value of preoperative serum CEA level compared to clinical staging. I. Colorectal carcinomaH J Staab, F A Anderer, T Brümmendorf, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1994
Enhancement of MHC-unrestricted cytotoxic activity of human CD56+ CD3- natural killer (NK) cells and CD3+ T cells by rhamnogalacturonan: target cell specificity and activity against NK-insensitive targetsH G Zhu, T M Zollner, A Klein-Franke, et al.
British Journal of Cancer|November 1, 1982
Doubling time of circulating cea and its relation to survival of patients with recurrent colorectal cancerH J Staab, F A Anderer, A Hornung, et al.
Oncodevelopmental Biology and Medicine : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 1980
Serial carcinoembryonic antigen (CEA) determinations in the management of patients with breast cancerH J Staab, L M Ahlemann, H L Koch, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|October 9, 1980
Is serum beta 2-microglobulin a tumor marker in gastrointestinal cancer?H J Staab, F A Anderer, K Hiesche, et al.
Deutsche Medizinische Wochenschrift (1946)|December 20, 1985
[Carcinoembryonic antigen: diagnosis and tumor progression in gastrointestinal tumors]T Brümmendorf, F A Anderer, H J Staab, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
Klinische Wochenschrift|February 4, 1985
The clinical validity of circulating tumor-associated antigens CEA and CA 19-9 in primary diagnosis and follow-up of patients with gastrointestinal malignanciesH J Staab, T Brümmendorf, A Hornung, et al.
Biochemical and Biophysical Research Communications|November 14, 1984
Cell fusion responsible for horizontal oncogenesis by human tumors in nude miceJ Kömpf, H J Staab, H Heilbronner, et al.
British Journal of Cancer|May 1, 1982
Prognostic value of preoperative serum CEA level compared to clinical staging: II. Stomach cancerH J Staab, F A Anderer, T Brümmendorf, et al.
Oncodevelopmental Biology and Medicine : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 1980
Carcinoembryonic antigen (CEA) measurements as an aid to management of patients with lung cancer treated by radiotherapyL M Ahlemann, H J Staab, H L Koch, et al.
British Journal of Cancer|November 1, 1981
Prognostic value of preoperative serum CEA level compared to clinical staging. I. Colorectal carcinomaH J Staab, F A Anderer, T Brümmendorf, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1994
Enhancement of MHC-unrestricted cytotoxic activity of human CD56+ CD3- natural killer (NK) cells and CD3+ T cells by rhamnogalacturonan: target cell specificity and activity against NK-insensitive targetsH G Zhu, T M Zollner, A Klein-Franke, et al.
British Journal of Cancer|November 1, 1982
Doubling time of circulating cea and its relation to survival of patients with recurrent colorectal cancerH J Staab, F A Anderer, A Hornung, et al.
Oncodevelopmental Biology and Medicine : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 1980
Serial carcinoembryonic antigen (CEA) determinations in the management of patients with breast cancerH J Staab, L M Ahlemann, H L Koch, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|October 9, 1980
Is serum beta 2-microglobulin a tumor marker in gastrointestinal cancer?H J Staab, F A Anderer, K Hiesche, et al.
Deutsche Medizinische Wochenschrift (1946)|December 20, 1985
[Carcinoembryonic antigen: diagnosis and tumor progression in gastrointestinal tumors]T Brümmendorf, F A Anderer, H J Staab, et al.
Pageof 9